Originally published as JCO Early Release 10.1200/JCO.2007.10.6815 on September 4 2007

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Brewster, A. M. Articles by Bondy, M. L. Search for Related Content PubMed PubMed Citation Articles by Brewster, A. M. Articles by Bondy, M. L.

Relationship Between Epidemiologic Risk Factors and Breast Cancer Recurrence

Abenaa M. Brewster, Kim-Anh Do, Patricia A. Thompson, Karin M. Hahn, Aysegul A. Sahin, Yumei Cao, Maureen M. Stewart, James L. Murray, Gabriel N. Hortobagyi, Melissa L. Bondy

From the Departments of Clinical Cancer Prevention, Biostatistics, Breast Medical Oncology, Pathology, and Epidemiology, The University of Texas M.D. Anderson Cancer Center, Houston, TX; and Department of Pathology, Arizona Cancer Center, The University of Arizona, Tucson, AZ

Address reprint requests to Abenaa M. Brewster, MD, MHS, Department of Clinical Cancer Prevention, Unit 1360, PO Box 301439, Houston, TX 77030; e-mail: abrewster{at}mdanderson.org

Purpose: Early-stage breast cancers are biologically heterogeneous and vary in clinical behavior, supporting the role of factors other than tumor size and lymph node involvement as outcome determinants. We evaluated the effect of epidemiologic breast cancer risk factors on recurrence in women with early-stage disease.

Patients and Methods: Medical records from 2,327 women with early-stage breast cancer, treated at the M.D. Anderson Cancer Center between 1985 and 2000, were used to derive information on epidemiologic, clinical, and histological factors. Cox proportional hazards models were used to estimate the hazard ratios of 5-year risk of breast cancer recurrence adjusted for treatment and stage. Statistical tests were two-sided.

Results: None of the breast cancer risk factors were associated with recurrence, adjusting for tumor characteristics and treatment. A significant interaction between hormone replacement therapy (HRT) use and tumor hormone receptor status on risk of recurrence (P = .0003) was observed. Among ever-users of HRT, recurrence risk was two-fold lower for estrogen receptor (ER) –positive and progesterone receptor (PR) –positive tumors compared with ER- and PR-negative tumors; whereas, among never-users of HRT, there was no statistically significant association between recurrence risk and receptor status.

Conclusion: HRT users who develop receptor-positive early-stage disease have better outcomes than those who develop receptor-negative disease. Among never-users of HRT, the expected beneficial effect of ER- or PR-positive tumors on recurrence risk was absent. These data lend support to the notion that the biology of hormone receptor–positive disease in HRT users differs from that in nonusers.

published online ahead of print at www.jco.org on September 4, 2007.

Supported by Grants No. R01 CA089608 (M.L.B.), R03CA123553 (A.M.B.), and Breast SPORE P50 CA116199 (G.N.H.) from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

This article has been cited by other articles:

				Do HT Use and Hormone-Receptor Status Affect Recurrence After Treatment for Early-Stage Breast Cancer? Journal Watch Oncology and Hematology, November 13, 2007; 2007(1113): 5 - 5. [Full Text]